piracetam has been researched along with Alcoholism in 32 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our data suggest that levetiracetam is not an appropriate treatment for non-treatment seeking alcohol abusers and can, in fact, increase their consumption of alcohol." | 9.16 | The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. ( Coker, AR; Grossman, LE; Messing, RO; Mitchell, JM, 2012) |
| "Our data suggest that levetiracetam is not an appropriate treatment for non-treatment seeking alcohol abusers and can, in fact, increase their consumption of alcohol." | 5.16 | The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. ( Coker, AR; Grossman, LE; Messing, RO; Mitchell, JM, 2012) |
| "This study suggests that levetiracetam deserves further study in the treatment of alcohol dependence and co-occurring anxiety disorders." | 5.13 | Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review. ( Levin, FR; Mariani, JJ, 2008) |
| "The levetiracetam XR treatment group showed significantly fewer consequences than did the placebo group during the maintenance period (p = 0." | 2.77 | A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. ( A Tompkins, D; Brunette, MF; Ciraulo, D; Devine, E; Falk, DE; Fertig, JB; Green, AI; Johnson, B; Kampman, K; Litten, RZ; Mattson, ME; Pettinati, H; Ransom, J; Rickman, WJ; Ryan, ML; Scott, C; Stout, R; Strain, EC; Tiouririne, NA, 2012) |
| "Diazepam was added when symptom triggered as rescue medication." | 2.75 | Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial. ( Heinz, A; Hinzpeter, A; Kienast, T; Plenge, T; Preuss, UW; Richter, C; Schaefer, M; Schmidt, F, 2010) |
| "Levetiracetam was well tolerated by most subjects." | 2.73 | The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. ( Afshar, M; Ciraulo, D; Devine, E; Knapp, C; Koplow, J; Piechniczek-Buczek, J; Richambault, C; Sarid-Segal, O; Sickles, L; Uwodukunda, E, 2008) |
| " After screening eligibility for outpatient detoxification, 9 alcohol-dependent patients received levetiracetam and tiapride in a flexible dosage regimen up to 2500 and 300 mg/d, respectively, for a maximum of 7 days." | 1.37 | A combination of levetiracetam and tiapride for outpatient alcohol detoxification: a case series. ( Banas, R; Förg, A; Heimann, HM; Hein, J; Heinz, A; Müller, CA; Schäfer, M; Volkmar, K, 2011) |
| "The findings of this study provide some evidence that levetiracetam is an efficacious and safe treatment option for outpatient alcohol detoxification." | 1.36 | Efficacy and safety of levetiracetam for outpatient alcohol detoxification. ( Förg, A; Heimann, HM; Hein, J; Heinz, A; Hinzpeter, A; Müller, CA; Schäfer, M; Schneider, S; Volkmar, K, 2010) |
| "Piracetam was found to markedly decrease the formation of neuronal lipofuscin." | 1.28 | The effects of piracetam on lipofuscin of the rat cerebellar and hippocampal neurons after long-term alcohol treatment and withdrawal: a quantitative study. ( Andrade, JP; Brandão, F; Cadete-Leite, A; Madeira, MD; Paula-Barbosa, MM; Pinho, MC, 1991) |
| "Finally it is suggested that insomnia and the loss of REM sleep may also contribute to the onset of the condition." | 1.27 | [Changes in the circadian rhythm of urinary cyclic adenosine monophosphate during the alcoholic withdrawal syndrome and related neurobiological correlations]. ( Cedaro, P; Di Piazza, V; Geatti, O; Lattuada, L; Marchetti, E; Nardoni, A, 1985) |
| " Long-term administration of piracetam or 3-oxypyridine derivative (300 and 50 mg/kg, respectively, i." | 1.27 | [Neurophysiological analysis of the correction by nootropic substances of disorders in the bioelectric activity of the brain in animals during chronic administration of ethanol]. ( Bogdanov, NN; Krapivin, SV; Voronin, KE, 1988) |
| "The enhanced seizure susceptibility after a single dose of ethanol was abolished by piracetam and MGO." | 1.27 | Influence of nootropic drugs on drinking behaviour in ethanol-preferring mice and ethanol-induced increase of seizure susceptibility. ( Andreas, K; Dienel, A; Schmidt, J, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (46.88) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 5 (15.63) | 29.6817 |
| 2010's | 10 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Youland, KM | 1 |
| Miller, RF | 1 |
| Mahoney, LJ | 1 |
| Borgert, AJ | 1 |
| Gundrum, JD | 1 |
| Sarid-Segal, O | 1 |
| Piechniczek-Buczek, J | 1 |
| Knapp, C | 1 |
| Afshar, M | 1 |
| Devine, E | 2 |
| Sickles, L | 1 |
| Uwodukunda, E | 1 |
| Richambault, C | 1 |
| Koplow, J | 1 |
| Ciraulo, D | 2 |
| Mariani, JJ | 1 |
| Levin, FR | 1 |
| Müller, CA | 2 |
| Schäfer, M | 2 |
| Schneider, S | 1 |
| Heimann, HM | 2 |
| Hinzpeter, A | 3 |
| Volkmar, K | 3 |
| Förg, A | 3 |
| Heinz, A | 5 |
| Hein, J | 2 |
| Richter, C | 3 |
| Schmidt, F | 1 |
| Kienast, T | 2 |
| Preuss, UW | 2 |
| Plenge, T | 1 |
| Schaefer, M | 3 |
| Zalewska-Kaszubska, J | 1 |
| Bajer, B | 1 |
| Czarnecka, E | 1 |
| Dyr, W | 1 |
| Gorska, D | 1 |
| Banas, R | 1 |
| Fertig, JB | 1 |
| Ryan, ML | 1 |
| Falk, DE | 1 |
| Litten, RZ | 1 |
| Mattson, ME | 1 |
| Ransom, J | 1 |
| Rickman, WJ | 1 |
| Scott, C | 1 |
| Green, AI | 1 |
| Tiouririne, NA | 1 |
| Johnson, B | 1 |
| Pettinati, H | 1 |
| Strain, EC | 1 |
| Brunette, MF | 1 |
| Kampman, K | 1 |
| A Tompkins, D | 1 |
| Stout, R | 1 |
| Mitchell, JM | 1 |
| Grossman, LE | 1 |
| Coker, AR | 1 |
| Messing, RO | 1 |
| Effenberger, S | 1 |
| Bschor, T | 1 |
| Bonnet, U | 1 |
| Haasen, C | 1 |
| Glauner, T | 1 |
| Le Strat, Y | 1 |
| Geisler, F | 1 |
| Smyth, M | 1 |
| Oechtering, J | 1 |
| Tuetuencue, S | 1 |
| Klostermann, F | 1 |
| Nolte, CH | 1 |
| Krebs, M | 1 |
| Leopold, K | 1 |
| Perfilova, VN | 2 |
| Ostrovskii, OV | 1 |
| Verovskii, VE | 1 |
| Popova, TA | 1 |
| Lebedeva, SA | 2 |
| Dib, H | 1 |
| Tiurenkov, IN | 1 |
| Parent, M | 1 |
| Jadot, M | 1 |
| Toussaint, C | 1 |
| Masson, AM | 1 |
| Kaiumov, BP | 1 |
| Sokolova, GB | 1 |
| Ziia, AV | 1 |
| Suvorova, VI | 1 |
| Braude, VI | 1 |
| Glik, MS | 1 |
| Entin, GM | 1 |
| Dencker, SJ | 1 |
| Wilhelmson, G | 1 |
| Carlsson, E | 1 |
| Bereen, FJ | 1 |
| Binder, S | 1 |
| Doddabela, P | 1 |
| Ulbricht, B | 1 |
| Godard, JP | 1 |
| Goerens, C | 1 |
| Grelier, C | 1 |
| Paula-Barbosa, MM | 1 |
| Brandão, F | 1 |
| Pinho, MC | 1 |
| Andrade, JP | 1 |
| Madeira, MD | 1 |
| Cadete-Leite, A | 1 |
| Salimov, RM | 1 |
| Viglinskaia, IV | 1 |
| Sluchevskiĭ, FI | 1 |
| Tikhomirov, SM | 1 |
| Bakharev, VD | 1 |
| Nardoni, A | 1 |
| Di Piazza, V | 1 |
| Marchetti, E | 1 |
| Geatti, O | 1 |
| Cedaro, P | 1 |
| Lattuada, L | 1 |
| Shabanov, PD | 1 |
| Grinenko, AIa | 1 |
| Kalishevich, SIu | 1 |
| Barnas, C | 2 |
| Miller, C | 2 |
| Gunther, V | 2 |
| Fleischhacker, WW | 2 |
| Krapivin, SV | 1 |
| Bogdanov, NN | 1 |
| Voronin, KE | 1 |
| Lieder, F | 1 |
| Dienel, A | 1 |
| Andreas, K | 1 |
| Schmidt, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome [Sicherheit Und Wirksamkeit Von Levetiracetam (Keppra) für Die Behandlung Des stationären Alkoholentzugsyndroms][NCT00146471] | Phase 3 | 120 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy Of Levetiracetam Extended Release in Very Heavy Drinkers[NCT00970814] | Phase 2 | 130 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients[NCT00758277] | Phase 3 | 201 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
based on self report (NCT00970814)
Timeframe: Study Weeks 5-14
| Intervention | drinks per day (Least Squares Mean) |
|---|---|
| Sugar Pill and BBCET | 6.3 |
| Levetiracetam and BBCET | 7.1 |
A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report. (NCT00970814)
Timeframe: Study Weeks 5-14
| Intervention | percentage of heavy drinking days (Least Squares Mean) |
|---|---|
| Sugar Pill and BBCET | 41.2 |
| Levetiracetam and BBCET | 45.8 |
A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report. (NCT00970814)
Timeframe: Weeks 5-14
| Intervention | percentage of subjects (Number) |
|---|---|
| Sugar Pill and BBCET | 18.2 |
| Levetiracetam and BBCET | 14.1 |
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
13 trials available for piracetam and Alcoholism
| Article | Year |
|---|---|
The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study.
Topics: Alcoholism; Anticonvulsants; Brain; Female; Humans; Levetiracetam; Male; Middle Aged; Piracetam; Rec | 2008 |
Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety Disorders; Diagnosis, Dual (Psychiatry); Female; Humans | 2008 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial.
Topics: Adult; Alcoholism; Anticonvulsants; Diazepam; Double-Blind Method; Female; Humans; Levetiracetam; Ma | 2010 |
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.
Topics: Adult; Affect; Aged; Alcoholism; Anticonvulsants; Anxiety; Breath Tests; Delayed-Action Preparations | 2012 |
The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers.
Topics: Alcohol Drinking; Alcoholism; Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; | 2012 |
Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Behavior, Addictive; Female; Humans; Levetirac | 2012 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Levetiracetam; Male; Middle Age | 2006 |
Piracetam and chlormethiazole in acute alcohol withdrawal: a controlled clinical trial.
Topics: Adult; Alcoholism; Chlormethiazole; Clinical Trials as Topic; Humans; Libido; Male; Middle Aged; Pir | 1978 |
[The efficacy of Piracetam on the mental functional capacity of chronic alcoholics (author's transl)].
Topics: Alcoholism; Behavior; Brain Damage, Chronic; Cerebellar Cortex; Clinical Trials as Topic; Female; Hu | 1976 |
[Clinical use of piracetam in chronic alcoholism and its complications predelirium and delirium].
Topics: Alcohol Withdrawal Delirium; Alcoholism; Clinical Trials as Topic; Drug Therapy, Combination; Halope | 1976 |
[Neuropeptides in the treatment of alcoholism and alcoholic psychoses].
Topics: Administration, Intranasal; Adrenocorticotropic Hormone; Adult; Alcohol Amnestic Disorder; Alcoholis | 1986 |
Treatment of alcohol organic mental disorder with piracetam.
Topics: Adult; Age Factors; Alcoholism; Clinical Trials as Topic; Cognition; Double-Blind Method; Female; Hu | 1987 |
Piracetam in alcoholic organic mental disorder: a placebo controlled study comparing two dosages.
Topics: Adult; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; | 1986 |
19 other studies available for piracetam and Alcoholism
| Article | Year |
|---|---|
Levetiracetam as adjunctive therapy for acute alcohol withdrawal syndrome in hospitalized patients.
Topics: Adult; Alcoholism; Anticonvulsants; Benzodiazepines; Cohort Studies; Drug Therapy, Combination; Fema | 2014 |
Efficacy and safety of levetiracetam for outpatient alcohol detoxification.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Ambulatory Care; Anticonvulsants; Female; Hum | 2010 |
Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: a preliminary study.
Topics: Alcohol Drinking; Alcoholism; Animals; Anticonvulsants; beta-Endorphin; Disease Models, Animal; Dose | 2011 |
A combination of levetiracetam and tiapride for outpatient alcohol detoxification: a case series.
Topics: Adult; Aged; Alcoholism; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Levetirace | 2011 |
Levetiracetam in the treatment of alcohol dependence: toward the end of the story?
Topics: Alcoholism; Anticonvulsants; Baclofen; Double-Blind Method; GABA Agonists; Humans; Levetiracetam; Pi | 2012 |
Auto-antibody-negative limbic-like encephalitis as the first manifestation of Neurosyphilis.
Topics: Aged; Alcoholism; Anticonvulsants; Autoantibodies; Cognition Disorders; Epilepsy, Generalized; Human | 2013 |
Effect of Citrocard on functional activity of cardiomyocyte mitochondria during chronic alcohol intoxication.
Topics: Alcoholism; Animals; GABA Agents; gamma-Aminobutyric Acid; Male; Mitochondria, Heart; Myocytes, Card | 2007 |
[Correction of cardiotoxic effect of chronic alcoholic intoxication by GABA-ergic compounds].
Topics: Alcoholism; Animals; Disease Models, Animal; Drug Therapy, Combination; GABA Agents; gamma-Aminobuty | 2007 |
[Alcohol withdrawal].
Topics: Alcoholism; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chlormethiazole; Humans; Par | 1982 |
[The effect of nootropil on the cerebral cortex ultrastructure in rats subjected to chronic alcoholic intoxication].
Topics: Alcoholism; Animals; Cerebral Cortex; Humans; Microscopy, Electron; Neurons; Piracetam; Pyrrolidinon | 1983 |
[Possibilities of using Nootropyl in the treatment of tuberculosis].
Topics: Adult; Alcoholism; Animals; Chemical and Drug Induced Liver Injury; Female; Hepatitis, Alcoholic; Hu | 1983 |
[Use of piracetam (nootropil) on alcoholism patients under ambulatory control of withdrawal manifestations].
Topics: Adult; Alcoholism; Ambulatory Care; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pi | 1981 |
Usefulness of piracetam in intensive care.
Topics: Alcoholism; Brain Diseases; Brain Injuries; Carbon Monoxide Poisoning; Cerebrovascular Disorders; Ch | 1976 |
The effects of piracetam on lipofuscin of the rat cerebellar and hippocampal neurons after long-term alcohol treatment and withdrawal: a quantitative study.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Animals; Cerebellum; Cytoplasmic Granules; Hippocampus; Lip | 1991 |
[Evaluation of accelerated development of stable alcoholic motivation in rats for studying potential alcohol deterrents].
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Carbazoles; Ethanol; Male; Motivation; Pi | 1990 |
[Changes in the circadian rhythm of urinary cyclic adenosine monophosphate during the alcoholic withdrawal syndrome and related neurobiological correlations].
Topics: Adult; Alcoholism; Circadian Rhythm; Clonidine; Cyclic AMP; Female; Humans; Piracetam; Sleep Initiat | 1985 |
[Use of preparations from the nootropic group for treating memory disorders in chronic alcoholism].
Topics: Adult; Alcoholism; Drug Evaluation; Etimizol; Humans; Imidazoles; Memory; Memory Disorders; Piraceta | 1988 |
[Neurophysiological analysis of the correction by nootropic substances of disorders in the bioelectric activity of the brain in animals during chronic administration of ethanol].
Topics: Alcoholism; Animals; Brain; Electroencephalography; Hippocampus; Male; Picolines; Piracetam; Pyrroli | 1988 |
Influence of nootropic drugs on drinking behaviour in ethanol-preferring mice and ethanol-induced increase of seizure susceptibility.
Topics: Alcohol Drinking; Alcoholism; Animals; Dihydroergotoxine; Ethanol; Male; Meglumine; Mice; Mice, Inbr | 1985 |